A Live Diagnostic Apollo Trial Follow-up, Cytori Therapeutics (CYTX)
A live diagnostic follow-up on a patient enrolled in the APOLLO study was performed and broadcast during the Euro PCR conference on 5/28/10 with this (single patient) outcome demonstrating sustained and further improvements at 18 months; in particular, improvements in infarct size and heart function.
This outcome is consistent with our observations at 6 months. On the example of this patient, impressive improvements in the infarct size and heart function was sustained with even further improvements at 18 months. Below is a summary of what was recorded from the live case as presented by Dr. Duckers:
- The patient is a 50 year old male who presented with ST-elevated myocardial infarction (heart attack) who underwent primary percutaneous coronary intervention 18 months ago,
- Contrast MRI infarct mass decreased from 37 gm, to 20 gm, to 19 gm at baselines, 6 months, and 18 months,
- Anterior, septal and apical defects as measured by SPECT all improved at 6 and 18 months.
During the live procedure, Dr. Duckers reviewed the recently reported 6 month results from the APOLLO trial and presented the following conclusions:
- Intracoronary infusion of ADRCs resulted in improved LVEF, reduced perfusion defect and reduced infarct size, based on the 6 month results reported in 5/10,
- Infarct size is one of the most important predictors for important clinical endpoints including re-hospitalization, subsequent infarct and death,
- The APOLLO study showed evidence of improved local contractility in the areas of the heart damaged by the heart attack.
The 5/28/10 diagnostic follow-up was performed at Erasmus University Hospital, an academic cardiology centers in Europe, and broadcast live to physicians attending a session at Euro PCR, the major European interventional cardiology meeting on potential new heart attack treatments. (Because the study is blinded, it’s unknown if the patient received adipose-derived stem and regenerative cells or placebo)
